Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1

81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results


31 Mar 2022


Mini Oral session 1


Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer


Chao Lyu


Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857


C. Lyu1, W. Fang2, W. Jiao3, H. Ma4, J. Wang1, S. Xu5, N. Wu6, R. Wang7, Y. Yang8

Author affiliations

  • 1 Beijing Cancer Hospital, Beijing/CN
  • 2 Shanghai Chest Hospital, Shanghai/CN
  • 3 Affiliated Hospital of Qingdao University, Qingdao/CN
  • 4 The First Affiliated Hospital of Soochow University, Soochow/CN
  • 5 Harbin Medical University Cancer Hospital, Harbin/CN
  • 6 Beijing Cancer Hospital, 100142 - Beijing/CN
  • 7 The Fourth Hospital of Hebei Medical University, Shijiazhuang/CN
  • 8 Peking University Cancer Hospital and Institute, 100142 - Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 81MO


Previously, the interim analysis of the multicenter, single-arm, phase 2 NEOS study (ChiCTR1800016948) demonstrated the promising efficacy and tolerable safety profile of neoadjuvant osimertinib in patients with resectable EGFR mutated NSCLC. Here we present the final efficacy and safety results of neoadjuvant osimertinib.


Eligible patients aged 18-75 with resectable, stage II-IIIB (T3-4N2), EGFR-mutant lung adenocarcinoma were enrolled and treated with osimertinib 80 mg once daily for six weeks followed by surgical resection. The primary endpoint was objective response rate assessed by investigator per RECIST v1.1. The secondary endpoints include safety, R0 resection rate, quality of life, major pathologic response (MPR) rate, pathological complete response (pCR) rate, and N2 downstaging rate.


Between October 17, 2018 and June 08, 2021, 88 patients were screened and 40 patients were finally enrolled. Of the 38 patients who completed 6-week osimertinib neoadjuvant treatment, the objective response rate was 71.1% (27/38). 32 patients underwent surgery (50% video-/robot-assisted thoracoscopic surgery; 50% open thoracotomy) and R0 resection was achieved in 30 (93.8%) of the resected patients. 10.7% of the 28 pathological evaluable patients achieved major pathological response, including one (3.6%) patient achieved pathological complete response. 13 (46.4%) patients had a ≥50% pathological response. Treatment-related adverse events (TRAEs) were observed in 24 (60%) patients during neoadjuvant treatment, including 3 (7.5%) had events of grade 3. No adverse event led to neoadjuvant treatment discontinuation occurred.


This study reported the data of neoadjuvant osimertinib in the largest prospective population to date. Osimertinib demonstrated satisfying efficacy and acceptable safety profile in the neoadjuvant setting and could be a promising therapy in patients with resectable EGFR mutated NSCLC.

Clinical trial identification


Legal entity responsible for the study

The authors.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.